Hologic Announces Fourth Quarter and Fiscal 2009 Operati...(155519 95310 Cost of revenu...),Health

Date:11/9/2009

155,519 95,310 Cost of revenues - impairment of acquired intangible assets 4,065 - Research and development 94,328 81,421 Selling and marketing 238,977 261,524 General and administrative 148,825 147,405 Amortization of acquired intangible assets 51,210 25,227 Restructuring charge 797 6,383 Impairment of goodwill 2,340,023 - Impairment of acquired intangible assets - 2,900 Acquired in-process research and development - 565,200 --- ------- 3,653,808 1,872,041 --------- --------- Loss from operations (2,016,674) (197,542) Interest income 1,161 4,528 Interest and other expense, net (73,162) (86,127) ------- ------- Loss before provision for income taxes (2,088,675) (279,141) Provision for income taxes 87,562 106,476 ------ ------- Net loss $(2,176,237) $(385,617) =========== ========= Net loss per common share: Basic $(8.48) $(1.57) ====== ====== Diluted $(8.48) $(1.57)
'/>"/>

SOURCE Hologic, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
Related medicine technology :

1. Three Year Analysis of Treatment Efficacy, Cosmesis, and Toxicity Support use of the Hologic Mammosite Radiation Therapy System
2. ALS Therapy Development Institute Partners with Clinical Centers to Establish Pathological Mechanisms of Lou Gehrigs Disease
3. Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials
4. Paclitaxel Poliglumex (OPAXIO(TM)) Added to Cisplatin and Radiation Produces 45% Pathologic Complete Remissions in Patients With Esophageal Cancer
5. Clinical and Histopathological Results Using Pollogens TriPollar(TM) Radio Frequency Technology Published in the June Issue of the Journal of Cosmetic and Laser Therapy
6. Hologic Receives CE Marking for the ThinPrep(R) Integrated Imager
7. OPAXIO Produces High Rates of Pathologic Complete Remission in Patients with Advanced Esophageal Cancer; Study Paves Way for Potential Registration Trial as Radiation Sensitizer
8. Hologic Expands Healthcare Investment in Asia
9. Hologic to Host Investor Reception at RSNA 2009
10. Hologic to Present at Citis 2009 Sixth Annual Small/Mid Cap Conference
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients